APA (7th ed.) Citation

Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W., Gallamini, A., . . . Straus, D. J. (2022). Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. The New England journal of medicine, 387(4), 310-320. https://doi.org/10.1056/NEJMoa2206125

Chicago Style (17th ed.) Citation

Ansell, Stephen M., et al. "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma." The New England Journal of Medicine 387, no. 4 (2022): 310-320. https://doi.org/10.1056/NEJMoa2206125.

MLA (9th ed.) Citation

Ansell, Stephen M., et al. "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma." The New England Journal of Medicine, vol. 387, no. 4, 2022, pp. 310-320, https://doi.org/10.1056/NEJMoa2206125.